Background: Ank
Methods
Structure-guided enhancement of the affinity of Ank GAG 1D4 towards the viral CA Ank GAG 1D4 residues, S45, Y56, R89, K122 and K123 were identified as key residues in the CA-binding. All key residues were substituted to the 20 natural amino acids (with the exception of S, Y, R or K, respectively for each case). Y56 was the major key residue of the CA-binding, while the other residues were secondary players in this interaction. These residues were categorized by the frequency of the interaction pairs as described in our previous paper. 15 In the CA/Ank GAG 1D4 complexes, the CA structure was fixed, and the Ank GAG 1D4 mutants were minimized by the algorithms of Steepest Descent and followed by Conjugate Gradient, based on CHARMM19 force field. The vdW values at positions 45, 56, 89, 122 and 123 in Ank GAG 1D4-CA mutants interacting with CA in our simulated models were compared to the residues found at the corresponding positions in parental Ank GAG 1D4.
Site-directed mutagenesis of Ank
GAG 1D4 Plasmid pQE30 encoding the full-length Ank GAG 1D4 was used for the amplification of the first ankyrin module (module#1) which contained the S45 or Y56 residues in standard PCR method. PCR was carried out using KOD Hot Start DNA polymerase (Novagen, Madison, WI). After purification, the amplified fragment was ligated into the pTZ57R/T acceptor vector, using the InsTAclone PCR Cloning Kit (Thermo Scientific, Rockford, IL). The ligation product was then introduced into the E.coli XL1-blue strain. The correctness of the clones was verified by standard sequencing method. The pTZ57R/T plasmid carrying the Ank GAG 1D4 module#1 was purified, and used as template for site-directed mutagenesis of S45 or Y56 residues by using the Quick change® lightening site-directed mutagenesis kit (Stratagene, La Jolla, CA).
Construction of expression vector encoding Ank GAG 1D4 mutants
The DNA fragments encoding module#1 mutants were amplified from the corresponding pTZ57R/T plasmids as above. The DNA fragment encoding the second module linked to the third module of Ank
Introduction
Antibodies have been implemented for many medical applications and represented the largest class of therapeutic proteins in clinical development. 1, 2 However, therapeutic antibodies have several limitations, such as their relatively high production cost, inefficient penetration and insufficient retention in targeted tissues. 3, 4 In addition, the major inconvenience is the requirement of disulfide bond formation to stabilize their structure and biological activity, a biochemical process which cannot occur in the reducing intracellular milieu. To address these limitations, non-immunoglobulin scaffolds have been proposed as alternatives to antibodies. 5, 6 These protein scaffolds were selected according to the following criteria: their high degree of solubility and stability, independence of disulfide bonds and/or glycosylation sites, their low cost of production, and their high affinity for their targets. 5 Ankyrins, and their artificial derivatives designed ankyrin repeat proteins (DARPins), are a novel class of protein binders designed for the recognition of a variety of molecular targets with high specificity and affinity. They are biologically active in various environments, including the extracellular milieu and intracellular compartments. [7] [8] [9] [10] Applications of artificial ankyrins to antiviral treatments are a new challenge for the future therapeutics, and recently, antiretroviral ankyrins have been designed to inhibit HIV-1 replication. This is the case for a CD4-specific DARPin, which competes with the HIV-1 envelope gp120 for CD4-receptor binding, and blocks the cell entry of divergent strains of HIV-1. 11 Likewise, a gp120 -reactive DARPin interacting with the V3 loop of gp120 acts as an efficient HIV-1 entry inhibitor. 12 Ank GAG 1D4 is a trimodular repeat protein which was selected from a phage-displayed ankyrin library for its binding to the HIV-1 capsid (CA). 13 Ank GAG 1D4 has been shown to possess a significant antiviral effect against HIV-1 replication.
13,14 HIV-1-infected SupT1 cells stably expressing Ank GAG 1D4 showed a significant reduction of the viral progeny yield, compared to control SupT1 cells. 13 Likewise, the N-myristoylated version of Ank GAG 1D4 was found to negatively interfere with HIV-1 replication in primary human CD4+ T-cells.
14 Ank GAG 1D4 showed a relatively high performance in terms of inhibition of viral particle assembly, but its efficacy, in terms of protection from HIV-1 infection, was not maximal, especially at late phase postinfection.
Increasing the affinity of Ank GAG 1D4 towards its viral target seemed therefore a well designated strategy to enhance the Ank GAG 1D4-mediated antiviral activity to obtain a complete HIV-1 inhibition. Several strategies are available to achieve this goal. In the present study, we used a relatively simple but rational approach through computational design, as an alternative to the time-consuming method of combinatorial design or directed evolution of ankyrin genes, using error-prone PCR in combination with in vitro selection of modified ankyrins by ribosome-display or phage-display. 9, 11 The goal of this study was to enhance binding affinity of Ank GAG 1D4 towards its viral target, through manipulation of selected amino acids belonging to the binding site or located in its close vicinity. Our choice of amino acid residues to modify in Ank 1D4 mutant proteins were produced and purified as described in detail elsewhere. 13, 15 Production of recombinant CA protein from bacterial cells
The recombinant CA protein was expressed following the protocol previously described. 15 The protein was purified by affinity chromatography on HisTrap column, using ÄKTA Prime™ plus (GE Healthcare, Piscataway, NJ). Protein concentration was measured using the Bradford protein assay kit (Pierce/Thermo Scientific, Rockford, IL) and analyzed by western blotting. In addition, the biotinylated CA was prepared by using EZ-Link™ Sulfo-NHS-LC-Biotinylation kit (Pierce/ Thermo Scientific, Rockford, IL) according to the procedure recommended by the manufacturer. 1D4 mutants to the CA protein was evaluated using AMELIA, a modification of the conventional ELISA, consisting of ankyrin-mediated capture of the target protein, followed by enzyme-linked immunoassay. 15 The microtiter plate was directly coated with recombinant Ank GAG 1D4 or Ank GAG 1D4 mutants at a final concentration of 5 µg/mL overnight at 4°C. Purified CA protein, diluted in PBS-2% bovine serum albumin (BSA), was added, and incubated at RT for 1h. After incubation, the excess amount of CA was removed using a conventional washing buffer (0.05% Tween-20 in PBS) or a high stringency washing buffer (1% Triton X100 (v/v) and 550 mM NaCl prepared in PBS (136.9 mM NaCl, 2.7 mM KCl, 8.1 mM Na 2 HPO 4 and 1.5 mM KH 2 PO 4 ), pH7.4). 16 The level of Ank GAG 1D4-mediated capture of the target CA protein was detected using the mouse monoclonal antibody against CA protein (M88), followed by HRP-conjugated goat anti-mouse immunoglobulin.
Evaluation

Binding kinetic analysis by bio-layer interferometry (BLI)
The binding kinetics of the Ank GAG 1D4 mutants with recombinant CA were measured using BLI performed with the BLItz™ system (ForteBio, Menlo Park, CA). All interaction analyses were conducted in sample diluent (bovine serum albumin (w/v, 2%) and tween-20 detergent (v/v, 0.05%) in PBS). Streptavidin (SA) biosensors were pre-wetted for 15 min in buffer immediately before use. The microplates used in the ForteBio system were filled with sample diluent for 250 µl/ well. Biotinylated CA protein at 100 µg/mL was immobilized to Streptavidin (SA) biosensors for 2 min. Next, saturated biosensors were washed in sample diluent for 30 sec and transferred to the tubes containing 10 µg/mL Ank To test the specificity, biotinylated interferon-γ (IFN-γ) which was also immobilized to SA biosensor, was used as irrelevant protein target served as negative control.
Determination of the CA ankyrinotope binding of Ank GAG -1D4-S45Y
AMELIA was applied to competitive system for analyzing the binding site on CA of Ank 
Results
Choice of amino acid residue(s) as target(s) for editing
Tyrosine at position 56 (Y56) in Ank GAG 1D4 was identified by molecular docking analysis as the key residue contributing the most to the binding of Ank GAG 1D4 to its viral partner. 15 The first step of our study was to experimentally verify that Y56 really played a crucial role in this interaction. If confirmed, this would designate Y56 as a candidate residue for the modulation of the binding affinity of Ank GAG 1D4 towards the CA. To this aim, we generated the substitution mutant Ank GAG 1D4-Y56A by site-directed mutagenesis of tyrosine at position 56 into alanine. The binding reactivity of Ank GAG 1D4 -Y56A recombinant protein to CA was evaluated by AMELIA, an ELISA-modified method based on the ankyrin-mediated capture of the target protein, followed by enzyme-linked immunoassay. 15 The parental ankyrin Ank GAG 1D4 showed a high CA-binding activity towards the viral CA protein, and the interaction observed between the two partners occurred in a CA concentration-dependent manner. In contrast, no CA -binding activity was detectable for the Ank GAG 1D4-Y56A mutant, at all CA concentrations tested ( Figure 1A) . This confirmed experimentally our previous prediction that Y56 was a first-rank key residue for the binding of HIV-1 CA, 15 and designated this residue as the best candidate for modification.
To further investigate on the role of residue Y56 in the binding of Ank GAG 1D4 to the CA, Ank GAG 1D4-Y56A mutant protein was purified to homogeneity and crystallized, and a structural analysis Ank GAG 1D4-Y56A crystal was performed. The structure of Ank GAG 1D4-Y56A crystal was determined at 1.9 Å resolution (accession codes 4ZFH). All X-ray crystallographic data and refinement statistics are summarized in Table 1 . The result demonstrated that the overall structure of Ank and CA protein was attributed the 100% value. The relative binding activity was calculated using the following formula: [OD mutant /OD parental ]×100. Data presented are from triplicate experiments (mean ± SD), analyzed using one-way ANOVA. ***P < 0.001 and ****P < 0.0001. alteration resulted from the substitution of tyrosine by alanine. This strongly suggested that the loss of CA-binding activity in Ank GAG 1D4-Y56A mutant was due to the loss of the tyrosine ring at position 56, and not to the overall conformation of the ankyrin mutant molecule.
Substitutions of the first-rank key residue at position 56: predictions and experimental results
The computational prediction using 3D docking structures and calculation of vdW binding forces suggested that none of the 19 natural amino acids which would substitute for Y56 would confer any significant affinity improvement to the Ank GAG 1D4 mutants ( Figure 1C) . This was experimentally confirmed by introducing some representatives of these substitutions into the recombinant ankyrin protein, viz. Y56D and Y56L. These two ankyrin mutants had lost their capacity to bind to the CA ( Figure 1D) . The results demonstrated that Y56 was the most critical residue in the interaction with CA partner and could not be substituted for any other amino acid without profoundly altering the affinity. and CA protein was attributed the 100% value. The relative binding activity was calculated using the following formula: [OD mutant / OD parental ]×100. Results presented are from triplicate experiments (mean ± SD), analyzed using one-way ANOVA. *P < 0.05, **P < 0.01. respectively, in the H7-mediated mode (Figure 2A) .
Position 45 corresponded to an interfacial residue located on an external loop of the Ank GAG 1D4, and of ankyrin molecules in general. Sequence comparison showed that the residues at position 45 in 96% of 500 ankyrin sequences available in Uniref90 database analyzed by ConSurf server 17, 18 were more hydrophilic than hydrophobic 19 (data not shown). Tyrosine is also less hydrophobic than tryptophan, therefore S45Y was selected as mutant, and the recombinant protein mutant Ank GAG 1D4-S45Y was generated as described above. As a further support to the vdW calculation-based prediction of S45 mutants, pocket analysis at position 45 showed that protein interaction within the 5Å-distance with ankyrin involved Q13 residue in the H1-mediated CA-ankyrin complex, and N139, K140, R143, M144 residues in the H7-mediated CA-ankyrin complex. Both pockets contributed to the binding through vdW bonds rather than through electrostatic interactions ( Figure  2E ).
Evaluation the effect of S-to-Y replacement at position 45 of Ank
GAG 1D4 mutant on the CA-binding activity To verify these predictions, the binding affinity of the Ank GAG 1D4-S45Y mutant towards the CA was evaluated by AMELIA in which a high-stringency washing buffer was introduced in the washing step, in order to eliminate nonspecific binding, and to discriminate between high and low affinity binder. 16 The results showed that the binding activity of Ank GAG 1D4-S45Y was significantly higher than parental Ank GAG 1D4, 60% under conventional conditions and 110 % under high stringency conditions (Figure 3) .
Substitutions of second-rank key residues
The results obtained with mutants at position 56 led us to consider substitutions of residues S45, R89, K122 and K123, which were identified as second-rank determinants of the interaction of Ank GAG 1D4 with CA, compared to Y56. 15 As for the amino acid screening at position 56, these four residues were substituted by a panel of 19 natural amino acids, and the corresponding vdW energy calculated and compared to that of the parental Ank GAG 1D4. Mutant residues with ΔvdW values lower than -2 kcal/mol were considered as good candidates for conferring to Ank GAG 1D4 mutants a higher affinity to the CA (Figure 2A-2D) . As previously, the selected mutations were introduced in the Ank GAG 1D4 gene, and the recombinant protein mutants analyzed in vitro for CA binding activity. In the case of K122 and K123, there was no substituent providing a ΔvdW lower than -2 kcal/mol (Figure 2C and 2D) . Likewise, R89 substitution by tryptophan or tyrosine residue resulted in ΔvdW values of -2.68 and -2.43 kcal/mol, respectively. These two values were only slightly lower than the threshold value of -2 kcal/mol, and were only obtained in the H7-mediated mode of CA-binding ( Figure 2B ).
In the case of S45 however, 11 amino acid substituents out of 19 showed a ΔvdW value significantly lower than -2 kcal/ mol (Figure 2A) . This implied that position 45 represented a privileged target for the modulation of the binding affinity of Ank GAG 1D4 towards the CA. In both H1-and H7-mediated modes of CA binding, tryptophan and tyrosine residues were the two residues at position 45 which showed the lowest ΔvdW values: -5.85 and -3.72 kcal/mol, respectively, in the H1-mediated mode of CA binding; -7.85 and -5.84 kcal/mol, 
Discussion
The effectiveness of protein scaffolds essentially depends on their affinity for their targets. The affinity of ankyrins can be enhanced by using various methods, including molecular design, to obtain picomolar range values for the affinity constant. 9 Several reports have described successful improvement of the binding affinity of interacting proteins using computationally guided molecular design. [20] [21] [22] [23] [24] Computational design is perfectly adapted to this particular goal, since individual amino acid residue(s), or limited protein domain(s), could be targeted and re-designed while maintaining the folding and three -dimensional structure of the whole molecule and its biological properties. 25 As applied to our antiviral scaffold Ank GAG 1D4, a binder of the HIV-1 CA protein, 13, 14 the logical start-point of our affinity enhancement strategy was the modification of amino acid residues which were crucial determinants of the interaction of Ank GAG 1D4 with the CA protein. These key residues are the main contributors to the binding energy, 20 and were previously identified in the Ank GAG 1D4 molecule docked to its CA target. 15 Tyrosine at position 56 (Y56), the first-rank key residue of the binding surface of Ank GAG 1D4, 15 was the first and privileged candidate for site-directed mutagenesis. However, the Y-to-A mutation at position 56 totally abolished the binding activity to the CA target. This result suggested that the first-rank key residue(s) responsible for the ankyrin-target stable interaction was untouchable, and that any type of substitution at such key position(s) would be detrimental to the binding reaction of ankyrin with its partner. This might be considered as a general guideline for future ankyrin re-engineering.
As a corollary, modifications of second-rank key residues seemed to be the best option to enhance the binding affinity of a given ankyrin to its specific target. S45, R89, K122 and K123 belonged to this class of second-rank key residues of the CA-Ank GAG 1D4 interaction. 15 For all positions defined as second-rank key residues, computational predictions revealed that S45Y substitution might confer a significant advantage over the parental Ank GAG 1D4 in terms of affinity towards the CA. This was experimentally confirmed using the recombinant mutant Ank GAG 1D4-S45Y. The equilibrium dissociation constant of the CA-Ank GAG 1D4-S45Y binding reaction was found to be in the nanomolar range of values (K D = 45 nM), i.e. 2.4-fold lower than with parental Ank GAG 1D4. Although modest, this augmentation of affinity was significant and would likely lead to net changes in their biological activities. [26] [27] [28] Several studies have shown that combined mutations, and not a single one, are necessary to obtain important increases in the affinity between protein partners. 23, 29 Mutation(s) of additional key residues in the Ank GAG 1D4-S45Y mutant backbone are therefore envisaged to further enhance the affinity of the Ank GAG 1D4-S45Y mutant for its HIV-1 target. These mutations should definitely respect the integrity of the site where the first-rank key residue Y56 resides.
The structural model of HIV-1 CA used in our previous and present studies was the monomeric form of crystallized CA_W184/M185A protein (PDB code: 2LF4), consisting of two independently folded domains, the N-terminal (CA NTD ) and C-terminal CA (CA CTD ) domains, joined by a flexible linker (YSPTS). Due to this linker, the CA monomer can occur under several isoforms. The three CA isoforms that we have previously chosen among the 20 possible different structures for our simulation of CA-Ank GAG 1D4 docking complexes provided an adequate representation of all CA-Ank GAG 1D4 complex candidates, and our results suggested that the parental Ank GAG 1D4 ankyrin was able to interact with any isoform of HIV-1 CA. 15 Our present results suggested that the S-to-Y mutation at position 45 did not alter the specificity of binding of the Ank In conclusion, we delineated the way to enhance the binding affinity of ankyrin scaffolds to their targets via computational design. This new strategy integrated in silico predictions through manipulation of key residues combined with vdW binding energy calculation, protein engineering technology and biophysical principle based on bio-layer interferometry analysis. This cross-disciplinary approach opened the way to further modifications and improvement of the binding affinity of next generation ankyrin scaffolds for therapeutic uses in the future. With respect to anti-HIV-1 biotherapy, modified antiviral ankyrins could be introduced into T-cells by episomal or lentiviral vectors in order to generate ankyrin-expressing, HIV-1-resistant cells, as described in our previous studies. 13, 14 To validate our concept, such antiviral ankyrins will be applied to hematopoietic stem cells for future clinical applications. 30 
